Bicycle Therapeutics Management
Management criteria checks 3/4
Bicycle Therapeutics' CEO is Kevin Lee, appointed in Sep 2015, has a tenure of 9.25 years. total yearly compensation is $5.54M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $3.62M. The average tenure of the management team and the board of directors is 2.9 years and 5.4 years respectively.
Key information
Kevin Lee
Chief executive officer
US$5.5m
Total compensation
| CEO salary percentage | 12.8% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.9yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern
Nov 07Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 03
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 23Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$166m |
| Jun 30 2024 | n/a | n/a | -US$165m |
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$6m | US$710k | -US$181m |
| Sep 30 2023 | n/a | n/a | -US$162m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$9m | US$673k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$677k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$62m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$592k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$4m | US$517k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$31m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$818k | US$386k | -US$22m |
Compensation vs Market: Kevin's total compensation ($USD5.54M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
CEO
Kevin Lee (56 yo)
9.3yrs
Tenure
US$5,540,400
Compensation
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 9.3yrs | US$5.54m | 0.37% $ 3.6m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 2.3m | |
| Chief Financial Officer | 1.4yrs | US$2.88m | no data | |
| Chief Development Officer | 1.8yrs | US$2.82m | 0% $ 0 | |
| Scientific Founder | no data | no data | no data | |
| Chief Operating Officer | 2.9yrs | US$5.98m | 0.024% $ 237.0k | |
| Senior VP | 1.5yrs | no data | 0% $ 0 | |
| Chief Technology Officer | 2.9yrs | US$3.07m | 0.073% $ 712.4k | |
| Senior Vice President of Investor Relations and Corporate Communications | no data | no data | no data | |
| Chief Legal Officer & General Counsel | 4.7yrs | no data | no data | |
| Head of Clinical and Project Management | 8.6yrs | no data | no data | |
| Senior VP of Pre-Clinical Development | 6.1yrs | no data | no data |
2.9yrs
Average Tenure
55.5yo
Average Age
Experienced Management: BCYC's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 9.3yrs | US$5.54m | 0.37% $ 3.6m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 2.3m | |
| Chairman of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Non-Executive Chairman | 5.8yrs | US$1.06m | 0.031% $ 303.8k | |
| Independent Non-Executive Director | 3.8yrs | US$482.29k | 0.016% $ 151.9k | |
| Independent Non-Executive Director | 5.4yrs | US$526.91k | 0.016% $ 151.9k | |
| Member of Scientific Advisory Board | 4.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.2yrs | no data | no data | |
| Independent Non-Executive Director | 5.4yrs | US$495.41k | 0.016% $ 151.9k | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.2yrs | no data | no data |
5.4yrs
Average Tenure
64yo
Average Age
Experienced Board: BCYC's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 22:47 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bicycle Therapeutics plc is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Kalpit Patel | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |